We are live on ! Find out more
KCM

Knoll Capital Management Portfolio holdings

AUM $180M
1-Year Est. Return 66.11%
This Fund
S&P 500
This Quarter Est. Return
+28.25%
1 Year Est. Return
+66.11%
3 Year Est. Return
+268.55%
5 Year Est. Return
+741%
10 Year Est. Return
+10,877.35%
AUM
$187M
AUM Growth
+$41.2M
Cap. Flow
+$6M
Cap. Flow %
3.2%
Top 10 Hldgs %
99.93%
Holding
13
New
2
Increased
2
Reduced
4
Closed
2

Top Buys

Rank Stock Value
1
VVUS
Vivus Inc
VVUS
+$6.24M
2
AMPE
Ampio Pharmaceuticals Inc.
AMPE
+$4.63M
3
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$536K
4
EXAS
Exact Sciences
EXAS
+$180K

Top Sells

Rank Stock Value
1
GNW icon
Genworth Financial
GNW
+$1.37M
2
MDVN
MEDIVATION, INC.
MDVN
+$1.14M
3
ECTE
ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE)
ECTE
+$1.08M
4
ACHN
Achillion Pharmaceuticals
ACHN
+$450K
5
SQNM
SEQUENOM INC NEW
SQNM
+$116K

Sector Composition

Rank Sector Weight
1 Healthcare 17.77%
2 Financials 1.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDVN
1
DELISTED
MEDIVATION, INC.
MDVN
$149M 79.45%
4,968,202
-40,000
-0.8% -$1.14M
AMPE
2
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$15.2M 8.11%
6,757
+2,395
+55% +$4.63M
ARCT icon
3
Arcturus Therapeutics
ARCT
$157M
$10.6M 5.65%
83,857
– –
VVUS
4
DELISTED
Vivus Inc
VVUS
$4.65M 2.48%
+50,000
New +$6.24M
GNW icon
5
Genworth Financial
GNW
$3.8B
$2.7M 1.44%
211,000
-109,000
-34% -$1.37M
SQNM
6
DELISTED
SEQUENOM INC NEW
SQNM
$2.39M 1.27%
893,600
-34,500
-4% -$116K
LUMO
7
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$1.45M 0.78%
8,604
+3,333
+63% +$536K
KERX
8
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$1.01M 0.54%
100,000
– –
CELG
9
DELISTED
Celgene Corp
CELG
$225K 0.12%
55,850
– –
EXAS
10
DELISTED
Exact Sciences
EXAS
$165K 0.09%
+14,000
New +$180K
ECTE
11
DELISTED
ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE)
ECTE
$123K 0.07%
44,445
-400,000
-90% -$1.08M
ACHN
12
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-55,000
Closed -$450K
VVUS
13
CALL
DELISTED
Vivus Inc
VVUS
– –
-500
Closed -$1.43M

Similar funds

MGWA
Monument Group Wealth Advisors Concord, Massachusetts $180M AUM 19.81% 1-Year Est. Return
AW
Alchemi Wealth Essex, Connecticut $180M AUM
FBC
Fairfield, Bush & Co Darien, Connecticut $180M AUM 39.51% 1-Year Est. Return
AIC
Aurora Investment Counsel Atlanta, Georgia $180M AUM 0.3% 1-Year Est. Return
AG
Amiral Gestion Paris, France $180M AUM 9.43% 1-Year Est. Return
PCA
Prospect Capital Advisors Sausalito, California $180M AUM 60.99% 1-Year Est. Return
HIC
Hamrick Investment Counsel Seattle, Washington $180M AUM
FFA
Frazier Financial Advisors Columbus, Ohio $181M AUM 11.16% 1-Year Est. Return

Knoll Capital Management's Q3 2013 Portfolio in Review

As of Q3 2013, Knoll Capital Management held 13 positions worth $187M, up 28% from $146M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Knoll Capital Management deployed $6M of net new capital in Q3 2013, opening 2 new positions and adding to 2 existing holdings. Its largest new stake was Vivus Inc: 50,000 shares worth $4.65M.

By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 9.5% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Genworth Financial, an estimated $1.37M trimmed.

  • Knoll Capital Management's largest Q3 2013 buy was Vivus Inc: 50,000 shares worth $4.65M.
  • Knoll Capital Management added most to Ampio Pharmaceuticals Inc. in Q3 2013, an estimated $4.63M increase.
  • Knoll Capital Management's biggest Q3 2013 reduction was Genworth Financial, cutting an estimated $1.37M.
  • Knoll Capital Management fully exited Achillion Pharmaceuticals in Q3 2013, selling an estimated $450K.
  • Knoll Capital Management's ten largest holdings make up 100% of its $187M portfolio in Q3 2013.
  • Knoll Capital Management opened 2 new positions and closed 2 in Q3 2013.
  • Knoll Capital Management's portfolio value rose 28% quarter-over-quarter to $187M.

Based on Knoll Capital Management's 13F filing for Q3 2013, filed 15 Nov 2013.